The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

The FDA has granted approval for the IND application of Everest Medicines’ tumour-associated antigen (TAA) vaccine, EVM14.

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

US FDA clears Everest Medicines’ IND application for tumour-associated antigen vaccine, EVM14: Shanghai, China Tuesday, March 25, 2025, 15:00 Hrs [IST] Everest Medicines, a biop ...

What’s Up With mRNA Research? A research nurse holds an injection of a BioNTech mRNA cancer immunotherapy for non-small cell ...

Mount Sinai scientists will continue studying PGV001 in larger groups of patients and testing how it works with other cancer treatments. Data from this phase 1 study have prompted three additional ...

For years, scientists worldwide have been experimenting with messenger RNA (mRNA) vaccines, unable to secure the funding or ...

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 ...